Quantcast

Novo Nordisk: Health Canada Approves Tresiba For Children With Type 1 Diabetes


Shutterstock photo


(RTTNews.com) - Novo Nordisk Canada Inc., a unit of Denmark-based healthcare company Novo Nordisk A/S (NVO), said that Tresiba, or insulin degludec injection, has received an expanded Health Canada approval for the treatment of pediatric patients, less than 2 years of age, with Type 1 diabetes mellitus.

Tresiba is an ultra-long-acting basal insulin which provides a glucose-lowering effect beyond 42 hours.

"For children living with Type 1 diabetes, blood sugar control remains one of the most significant challenges of managing the disease. We are pleased that this announcement means more individuals will have a new treatment option available to assist in combatting this challenge at all stages of the disease," said Dave Prowten, President and CEO of JDRF.

Diabetes is the most frequently diagnosed endocrine disease occurring in children, and is one of the most common chronic conditions among this group. Annually, 86,000 children develop Type 1 diabetes globally, and Canada has one of the highest incidence rates for children under 14 years of age.

The expanded indication of Tresiba follows its first Health Canada approval in August 2017 for the treatment of adults with Type 1 and Type 2 diabetes mellitus.

Tresiba has been approved for reimbursement for adults with Type 1 and Type 2 diabetes mellitus in Ontario, effective September 27, 2018, Quebec, effective September 27, 2018, Saskatchewan, effective October 1, 2018, Manitoba, effective October 18, 2018, as well as by the Non-Insured Health Benefits Program, effective September 18, 2018.

Tresiba was also the first insulin added to the Register of Innovative Drugs for human use.


Read the original article on RTTNews (http://www.rttnews.com/2939673/novo-nordisk-health-canada-approves-tresiba-for-children-with-type-1-diabetes.aspx)


For comments and feedback: contact editorial@rttnews.com




This article appears in: Stocks , World Markets , Economy



More from RTT News

Subscribe






See All RTT news











Research Brokers before you trade

Want to trade FX?